TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32635680

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 0
Study: 32636288

Group type: EXPERIMENTAL
Intervention: Diagnostic pathway for autism assessment, compliant with NICE guidelines, aimed to be completed within 13 weeks.
Number of subjects: 0
Study: 32636632

Group type: EXPERIMENTAL
Intervention: Fulvestrant (FUL)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Everolimus plus Exemestane (EVE-EXE)
Number of subjects: 168
Study: 32636771

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment for 1 year
Number of subjects: 301
Study: 32636943

Group type: EXPERIMENTAL
Intervention: Low-pressure hyperbaric oxygen therapy (HBOT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Physical exercise program (PEG)
Number of subjects: 49
Study: 32637360

Group type: EXPERIMENTAL
Intervention: Cetuximab plus Docetaxel and Cisplatin regimen
Number of subjects: 0
Study: 32637723

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (predominantly Roux-en-Y gastric bypass)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intensive non-surgical treatment starting with an eight-week low-calorie diet
Number of subjects: 50
Study: 32637895

Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 100
Study: 32637901

Group type: EXPERIMENTAL
Intervention: Standard BI (in-person problem-solving skills training)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Web-based BI (mobile device problem-solving skills training)
Number of subjects: 621
Study: 32637899

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy (NCRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy (NCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 32638098

Group type: EXPERIMENTAL
Intervention: 18F-FAZA PET/CT
Number of subjects: 20
Study: 32638211

Group type: EXPERIMENTAL
Intervention: 7-panel mutation testing
Number of subjects: 131
Study: 32638247

Group type: EXPERIMENTAL
Intervention: Vitamin D/calcium deficiency assessment before bariatric-metabolic surgery
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Evaluation of 25(OH)D threshold for maximal suppression of parathyroid hormone (PTH)
Number of subjects: 52
Study: 32638703

Group type: EXPERIMENTAL
Intervention: Toi Même app for self-monitoring mood and behavioral parameters
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Toi Même app
Number of subjects: 93
Study: 32639409

Group type: EXPERIMENTAL
Intervention: Baseline median galectin-3 level of 21.1 ng/mL (interquartile range, 17.0-27.2)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Galectin-3 levels in the highest tertile
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: KTR with systolic blood pressure ≥140 mmHg
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: KTR with smoking history
Number of subjects: 561
Study: 32639484

Group type: EXPERIMENTAL
Intervention: Intensive speech treatment targeting voice (16 1-hour sessions/1 month)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intensive speech treatment targeting articulation (16 1-hour sessions/1 month)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Untreated group (no treatment)
Number of subjects: 64
Study: 32639485

Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18
Number of subjects: 546

Group type: COMPARATOR
Intervention: 4vHPV
Number of subjects: 546
Study: 32639845

Group type: EXPERIMENTAL
Intervention: Complete macroscopic excision (CME) in 1,172 patients (77%)
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Incomplete macroscopic resection (IME) in 359 patients (23%)
Number of subjects: 1531
Study: 32640200

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Histologic and cytologic typing
Number of subjects: 33
Study: 32640370

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study: 32640944

Group type: EXPERIMENTAL
Intervention: Utility-Weighted Modified Rankin Scale (UW-mRS) scores derived from linear regression
Number of subjects: 22946

Group type: EXPERIMENTAL
Intervention: UW-mRS scores as a continuous variable
Number of subjects: 22946

Group type: EXPERIMENTAL
Intervention: Area under receiver operator characteristic curves based on EQ-5D utility values
Number of subjects: 22946

Group type: EXPERIMENTAL
Intervention: Misclassification matrix
Number of subjects: 22946
Study: 32641009

Group type: EXPERIMENTAL
Intervention: Enhanced Individual Placement and Support (IPS) intervention
Number of subjects: 0
Study: 32641032

Group type: EXPERIMENTAL
Intervention: Community-based adherence clubs
Number of subjects: 129

Group type: COMPARATOR
Intervention: Local primary health care clinic (PHC)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both adherence clubs and PHC
Number of subjects: 129
Study: 32641071

Group type: EXPERIMENTAL
Intervention: Patisiran (0.3 mg/kg intravenously every 3 weeks)
Number of subjects: 27
Study: 32641131

Group type: EXPERIMENTAL
Intervention: 0.02% polihexanide solution used for catheter irrigation on five consecutive days
Number of subjects: 15
Study: 32641261

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks (Q2W) for ≤ 24 months or until confirmed progression/unacceptable toxicity
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks (Q2W)
Number of subjects: 97
Study: 32641418

Group type: EXPERIMENTAL
Intervention: Intracranial blood protein expression
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Endopeptidase
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Phospholipid transfer protein (PLTP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Uromodulin (UMOD)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ficolin-2 (FCN2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: C-C motif chemokine 19 (CCL19)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: C-C motif chemokine 20 (CCL20)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 21
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: C-C motif chemokine (CCL23)
Number of subjects: 25
Study: 32641862

Group type: EXPERIMENTAL
Intervention: Single-agent palbociclib
Number of subjects: 196
Study: 32642149

Group type: EXPERIMENTAL
Intervention: AG NPP709
Number of subjects: 30
Study: 32642592

Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu (FZHY) tablets and entecavir
Number of subjects: 350
Study: 32642704

Group type: EXPERIMENTAL
Intervention: Marizomib (MRZ)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Bortezomib (BTZ)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Carfilzomib (CFZ)
Number of subjects: 3
Study: 32642768

Group type: EXPERIMENTAL
Intervention: Continuous rhythm monitoring (implantable loop recorder or pacemaker) for 6 months
Number of subjects: 202
Study: 32642992

Group type: EXPERIMENTAL
Intervention: FACT-EGFRI 18
Number of subjects: 124
Study: 32643012

Group type: EXPERIMENTAL
Intervention: Proximal approach for US-guided axillary vein catheterization (AVC)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Distal approach for US-guided axillary vein catheterization (AVC)
Number of subjects: 198
Study: 32643100

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (US) during catheter insertion
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (US) after adjustment for confounders
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Skin colonization at catheter removal
Number of subjects: 3029
Study: 32643995

Group type: EXPERIMENTAL
Intervention: Ketamine infusions (6 infusions over 2 weeks)
Number of subjects: 13
Study: 32644197

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) RNFL thickness measurements
Number of subjects: 70

Group type: COMPARATOR
Intervention: Computed tomography measurements
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Longitudinal assessment of RNFL thickness
Number of subjects: 70
Study: 32644818

Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor
Number of subjects: 0
Study: 32645016

Group type: EXPERIMENTAL
Intervention: Fadraciclib (CYC065)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fadraciclib (CYC065) in combination with BCL2 inhibitors (e.g., venetoclax)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fadraciclib
Number of subjects: 0
Study: 32645113

Group type: EXPERIMENTAL
Intervention: Caregivers
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Concern about dying
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Unspecified concerns
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Overall concerns
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Severity of disease concern
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Functional decline concern
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Dying concern
Number of subjects: 594
Study: 32645153

Group type: EXPERIMENTAL
Intervention: Inhibitors of the renin-angiotensin-aldosterone system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32645282

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 68
Study: 32645640

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (600 mg treatment cycles at week 0, 24, 48, 72)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (600 mg treatment cycles)
Number of subjects: 55
Study: 32646305

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography imaging of nonculprit lesions
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Obstructive nonculprit lesions
Number of subjects: 93

Group type: COMPARATOR
Intervention: Nonobstructive lesions
Number of subjects: 93
Study: 32646369

Group type: EXPERIMENTAL
Intervention: Cap-assisted endoscopy (CAE)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard forward-viewing endoscopy (FVE)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Endoscopists
Number of subjects: 102
Study: 32646574

Group type: EXPERIMENTAL
Intervention: Early cardioversion without anticoagulation
Number of subjects: 0
Study: 32646588

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) intravenously at the end of the endometriosis resection
Number of subjects: 21
Study: 32646955

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI) assessment of white matter integrity in ALS patients
Number of subjects: 66

Group type: COMPARATOR
Intervention: Diffusion tensor imaging (DTI) assessment of white matter integrity in healthy controls
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Comparison of fast vs slow progression in ALS patients
Number of subjects: 66
Study: 32647053

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study: 32647531

Group type: EXPERIMENTAL
Intervention: Apple extract (AE, 2.0 g)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mulberry fruit extract (MFE, 1.5 g)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract (MLE, 1.0 g)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Elderberry extract (EE, 2.0 g)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Turmeric extract (TE, 0.18 g)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: White bean extract (WBE, 3.0 g)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: AE + TE
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: EE + TE
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (rice porridge with ~50 g available carbohydrate)
Number of subjects: 72
Study: 32647975

Group type: EXPERIMENTAL
Intervention: Etelcalcetide (0.035 mg/kg intravenously)
Number of subjects: 11
Study: 32648087

Group type: EXPERIMENTAL
Intervention: Therapeutic approaches targeting the NLRP3 inflammasome and its downstream signaling cascade
Number of subjects: 0

Group type: COMPARATOR
Intervention: NLRP3 inflammasome
Number of subjects: 0
Study: 32648108

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 4859

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 4859

Group type: EXPERIMENTAL
Intervention: Ertugliflozin (both doses)
Number of subjects: 4859

Group type: COMPARATOR
Intervention: Non-ertugliflozin
Number of subjects: 4859
Study: 32648205

Group type: EXPERIMENTAL
Intervention: Remote Electrical Neuromodulation (REN)
Number of subjects: 38
Study: 32648248

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 367
Study: 32648303

Group type: EXPERIMENTAL
Intervention: 500-mg ivosidenib in participants with mild hepatic impairment
Number of subjects: 33
Study: 32648959

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 5443
Study: 32649004

Group type: EXPERIMENTAL
Intervention: Neoadjuvant bevacizumab (5 mg/kg) with modified FOLFOX7 (oxaliplatin 85 mg/m2) for six cycles
Number of subjects: 17
Study: 32649037

Group type: EXPERIMENTAL
Intervention: Supersaturated oxygen (SSO) therapy for 60 minutes
Number of subjects: 100
Study: 32649498

Group type: EXPERIMENTAL
Intervention: Candy Cane
Number of subjects: 138

Group type: COMPARATOR
Intervention: Boot Stirrups
Number of subjects: 138
Study: 32649866

Group type: EXPERIMENTAL
Intervention: Post-transplant cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis and an optimized ART strategy including enfuvirtide.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Post-transplant cyclophosphamide and optimized ART strategy.
Number of subjects: 9
Study: 32649919

Group type: EXPERIMENTAL
Intervention: Circulating tumour cells (CTCs) detection using the isolation by size of epithelial tumour cell technique (ISET)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Low-dose chest CT (LDCT) screening
Number of subjects: 614
Study: 32650305

Group type: EXPERIMENTAL
Intervention: Self-reported symptoms of SARS-CoV-2 infection (myalgia, olfactory and taste disorders, cough, fever)
Number of subjects: 4392

Group type: EXPERIMENTAL
Intervention: Self-reported symptoms in nontested population
Number of subjects: 4392
Study: 32650731

Group type: EXPERIMENTAL
Intervention: CAIDE85+ study intervention including cognitive evaluations (CERAD, Trail Making Test-A, Letter-Digit Substitution Test, Clinical Dementia Rating, Activities of Daily Living) and assessments of physical health status, psychosocial wellbeing, and blood biomarkers relevant for dementia and ageing.
Number of subjects: 2900
Study: 32650734

Group type: EXPERIMENTAL
Intervention: Elective colorectal surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General medicine with acute bacterial infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient Reported Outcome Measures Information System and Short Physical Performance Battery
Number of subjects: 0
Study: 32650781

Group type: EXPERIMENTAL
Intervention: French WHOQOL-HIV BREF
Number of subjects: 586
Study: 32651242

Group type: EXPERIMENTAL
Intervention: MRI-guided focused ultrasound (MRgFUS) thalamotomy
Number of subjects: 94
Study: 32651241

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss in people with obesity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lean healthy people
Number of subjects: 0
Study: 32651674

Group type: EXPERIMENTAL
Intervention: JAAM-DIC score
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: ISTH overt-DIC score
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: SIC score
Number of subjects: 582

Group type: COMPARATOR
Intervention: SIC score combined with JAAM-DIC score
Number of subjects: 582

Group type: COMPARATOR
Intervention: SIC score combined with ISTH overt-DIC score
Number of subjects: 582
Study: 32651887

Group type: EXPERIMENTAL
Intervention: Extended release naltrexone treatment starting in the week prior to release from prison
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Training to use naloxone rescue kits and provision of nasal naloxone at release
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ongoing support from a certified recovery mentor for 6 months post-release
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison group of females released from prison during the study period
Number of subjects: 100
Study: 32651996

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies prescribed after percutaneous coronary intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32652034

Group type: EXPERIMENTAL
Intervention: Low n-6:n-3 PUFA ratio diet (4:1) for 12 weeks
Number of subjects: 20
Study: 32652442

Group type: EXPERIMENTAL
Intervention: Pamiparib (3 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Pamiparib with Temozolomide (TMZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pamiparib
Number of subjects: 0
Study: 32653053

Group type: EXPERIMENTAL
Intervention: Margetuximab 15 mg/kg plus pembrolizumab 200 mg intravenously every 3 weeks (recommended phase 2 dose)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Margetuximab 10 mg/kg plus pembrolizumab 200 mg intravenously every 3 weeks (dose-escalation phase)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Margetuximab plus pembrolizumab
Number of subjects: 95
Study: 32653445

Group type: EXPERIMENTAL
Intervention: Insufficient calorie intake (<90% of metabolic needs)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Insufficient calorie intake
Number of subjects: 57
Study: 32653622

Group type: EXPERIMENTAL
Intervention: Ixazomib (4 mg, oral, weekly for 4 doses from days +60 to +90)
Number of subjects: 57

Group type: COMPARATOR
Intervention: CIBMTR controls (matched contemporaneous controls)
Number of subjects: 57
Study: 32654183

Group type: EXPERIMENTAL
Intervention: Not applicable (no intervention reported, observational study)
Number of subjects: 304
Study: 32654363

Group type: EXPERIMENTAL
Intervention: Open radical prostatectomy (ORP)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy (RARP)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Pelvic lymph node dissection (PLND)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Stage pT3b disease
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Postoperative opioid use (inpatient)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Postoperative opioid use (outpatient)
Number of subjects: 500
Study: 32654558

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 13764

Group type: COMPARATOR
Intervention: No beta-blocker therapy
Number of subjects: 13764
Study: 32654872

Group type: EXPERIMENTAL
Intervention: Valiant Captivia thoracic stent graft (Medtronic Inc)
Number of subjects: 50
Study: 32655854

Group type: EXPERIMENTAL
Intervention: High-dose scopolamine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Low-dose scopolamine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (0.9% saline i.m.)
Number of subjects: 66
Study: 32655940

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg (0.05 ml) bevacizumab followed by phacoemulsification, pars plana vitrectomy (PPV) including panretinal photocoagulation (PRP), and trabeculectomy with mitomycin C (MMC)
Number of subjects: 12
Study: 32656160

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of candesartan (16 mg) and amlodipine (10 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Coadministration of individual formulations of candesartan (16 mg) and amlodipine (10 mg)
Number of subjects: 39
Study: 32657017

Group type: EXPERIMENTAL
Intervention: Dermatofluoroscopy
Number of subjects: 476
Study: 32657505

Group type: EXPERIMENTAL
Intervention: Sebelipase alfa (1.0 or 3.0 mg/kg every other week) for up to 5 years
Number of subjects: 8
Study: 32657973

Group type: EXPERIMENTAL
Intervention: Betrixaban or Rivaroxaban
Number of subjects: 3

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 3
Study: 32658300

Group type: EXPERIMENTAL
Intervention: Assessment with urinary dipstick and creatinine at admission, followed by urinary sediment and quantification of albuminuria if positive.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory treatment discussed with a nephrologist.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuation of ACEi/ARBs treatment if possible.
Number of subjects: 0
Study: 32658601

Group type: EXPERIMENTAL
Intervention: Maternal gut microbiota
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Meconium microbiota of very preterm neonates (born after 28 gestational weeks)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Meconium microbiota of extremely preterm neonates (born before 28 gestational weeks)
Number of subjects: 117
Study: 32658816

Group type: EXPERIMENTAL
Intervention: Manic phase (before treatment)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Manic phase (SA analysis)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Euthymic phase (post treatment)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 32659272

Group type: EXPERIMENTAL
Intervention: Mitochondrial oxidative capacity measurement in permeabilized muscle fibers using high-resolution respirometry
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Expression of circadian core clock genes BMAL1 and REV-ERBα
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Expression of repressor clock gene PER2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Expression of clock genes PER1 and PER3
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resting energy expenditure measurement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Respiratory exchange ratio measurement
Number of subjects: 12
Study: 32659786

Group type: EXPERIMENTAL
Intervention: Glucocorticoids administration
Number of subjects: 3

Group type: COMPARATOR
Intervention: Selective blockade of CXCR4
Number of subjects: 3
Study: 32660310

Group type: EXPERIMENTAL
Intervention: Coronary flow capacity (CFC) classification: normal, mildly reduced, moderately reduced, severely reduced
Number of subjects: 133
Study: 32660467

Group type: EXPERIMENTAL
Intervention: Laparoscopy with intracorporeal anastomosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopy with extracorporeal anastomosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery with intracorporeal anastomosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery with extracorporeal anastomosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0